745875
Last Update Posted: 2012-06-06
Recruiting has ended
All Genders accepted | 18 Years + |
66 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone
Eligibility
Relevant conditions:
Non Small Cell Lung Cancer
Lung Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov